NASDAQ:AFIB - Acutus Medical Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $11.80
  • Forecasted Upside: 343.61 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.66
▼ -0.36 (-11.92%)

This chart shows the closing price for AFIB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Acutus Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AFIB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AFIB

Analyst Price Target is $11.80
▲ +343.61% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Acutus Medical in the last 3 months. The average price target is $11.80, with a high forecast of $19.00 and a low forecast of $3.00. The average price target represents a 343.61% upside from the last price of $2.66.

This chart shows the closing price for AFIB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in Acutus Medical.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/14/2022Canaccord Genuity GroupLower Price TargetBuy ➝ Hold$10.00 ➝ $3.00High
1/14/2022UBS GroupDowngradeBuy ➝ HoldHigh
11/29/2021BTIG ResearchReiterated RatingBuy$8.00High
11/12/2021BTIG ResearchLower Price TargetNeutral ➝ Buy$20.00 ➝ $8.00High
11/12/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
10/22/2021The Goldman Sachs GroupInitiated CoverageNeutral$10.00High
3/25/2021JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$19.00Low
3/25/2021William BlairReiterated RatingOutperform ➝ Market PerformLow
3/19/2021William BlairDowngradeOutperform ➝ Market Perform$39.00 ➝ $19.00High
3/19/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$39.00 ➝ $19.00High
1/14/2021Bank of AmericaDowngradeBuy ➝ Neutral$38.00 ➝ $30.00Low
9/17/2020BTIG ResearchReiterated RatingBuy$40.00High
8/31/2020William BlairInitiated CoverageOutperformHigh
8/31/2020BTIG ResearchInitiated CoverageBuy$40.00High
8/31/2020Bank of AmericaInitiated CoverageBuy$38.00High
8/31/2020JPMorgan Chase & Co.Initiated CoverageOverweight$39.00High
(Data available from 1/18/2017 forward)

News Sentiment Rating

0.65 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 9 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/20/2021
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/19/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/18/2022

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Acutus Medical logo
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is based in Carlsbad, California.
Read More

Today's Range

Now: $2.66
Low: $2.51
High: $2.83

50 Day Range

MA: $3.60
Low: $2.66
High: $7.68

52 Week Range

Now: $2.66
Low: $2.51
High: $29.95

Volume

759,396 shs

Average Volume

417,430 shs

Market Capitalization

$74.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Acutus Medical?

The following Wall Street sell-side analysts have issued stock ratings on Acutus Medical in the last year: BTIG Research, Canaccord Genuity Group Inc., JPMorgan Chase & Co., The Goldman Sachs Group, Inc., UBS Group AG, William Blair, and Zacks Investment Research.
View the latest analyst ratings for AFIB.

What is the current price target for Acutus Medical?

5 Wall Street analysts have set twelve-month price targets for Acutus Medical in the last year. Their average twelve-month price target is $11.80, suggesting a possible upside of 343.6%. JPMorgan Chase & Co. has the highest price target set, predicting AFIB will reach $19.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $3.00 for Acutus Medical in the next year.
View the latest price targets for AFIB.

What is the current consensus analyst rating for Acutus Medical?

Acutus Medical currently has 1 sell rating, 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AFIB, but not buy more shares or sell existing shares.
View the latest ratings for AFIB.

What other companies compete with Acutus Medical?

How do I contact Acutus Medical's investor relations team?

Acutus Medical's physical mailing address is 2210 FARADAY AVE SUITE 100, CARLSBAD CA, 92008. The company's listed phone number is 442-232-6080 and its investor relations email address is [email protected] The official website for Acutus Medical is www.acutusmedical.com.